Latest News

Key Insights The considerable ownership by public companies in HUYA indicates that they collectively have a greater say...

Erayak Power Solution Group Inc. ( NASDAQ:RAYA ) shareholders are no doubt pleased to see that the share price has...

EyePoint, Inc. (formerly EyePoint Pharmaceuticals, Inc.) recently secured a positive safety recommendation to continue its Phase 3 DURAVYU trials and filed a prospectus supplement for a Controlled Equity Offering of up to US$200,000,000 in common stock, while a major insider modestly reduced her holdings. The combination of a clean safety review for DURAVYU and a sizable at-the-market equity program highlights both the company’s clinical momentum and its need to fund a capital-intensive...

It's not a stretch to say that Northern Oil and Gas, Inc.'s ( NYSE:NOG ) price-to-sales (or "P/S") ratio of 1.1x right...

Coloplast (CPSE:COLO B) packed a lot into its December AGM, with a refreshed boardroom lineup and an approved year end dividend of DKK 18 per share, both giving investors fresh angles to reassess the stock. See our latest analysis for Coloplast. Those boardroom changes and the confirmed dividend land against a weaker backdrop, with a 1 year total shareholder return of roughly negative 31 percent and year to date share price return of about negative 28 percent, suggesting momentum has been...

Expedia Group (EXPE) just doubled down on two big themes driving its business by launching a Set Jetting travel hub for screen inspired trips and appointing its first chief AI and data officer. See our latest analysis for Expedia Group. Those moves come as momentum builds in the stock, with a 21.46% 3 month share price return and a 42.67% year to date share price return contributing to a 178.81% 3 year total shareholder return. If this kind of thematic growth story appeals to you, it could be...

Extendicare Inc. ( TSE:EXE ) shareholders (or potential shareholders) will be happy to see that the Independent...

Appian (APPN) just picked up global recognition in healthcare tech, with its joint “Bring AI to Work(flow)” solution winning the HL7 AI Challenge for interoperable and ethical AI driven workflows in patient care. See our latest analysis for Appian. That backdrop of validation seems to be feeding into sentiment, with a 90 day share price return of 31.54 percent pushing Appian to 29.68 percent year to date. However, the five year total shareholder return remains sharply negative and reminds...

Nebius Group (NBIS) just locked in multi billion dollar AI infrastructure deals with Microsoft and Meta, but the stock is wobbling as investors weigh that growth story against rising debt and a stretched valuation. See our latest analysis for Nebius Group. Those mega deals arrive after a wild run, with Nebius delivering a soaring year to date share price return of 228.84 percent but cooling off with a 30 day share price return of negative 9.84 percent, suggesting momentum is pausing rather...

Key Insights Significantly high institutional ownership implies Cognyte Software's stock price is sensitive to their...

State Street (STT) has quietly ground out steady gains this year, and its recent move higher is catching more investor attention. With the stock up roughly 27% year to date, the question is whether that momentum still looks reasonable. See our latest analysis for State Street. The steady climb in State Street’s share price to about $124, alongside a 12.0% 3 month share price return and a 27.9% 1 year total shareholder return, suggests momentum is still building rather than fading. If you are...

In November 2025, Ameriprise Financial announced that Houston-based Harpland Financial Management joined its branch channel from Wells Fargo Clearing Services with more than US$160 million in client assets, bringing advisors Peter Horton and Serena Sneeringer and client service associate Micah Horton onto its platform. This move underscores growing adviser interest in Ameriprise’s technology, integrated planning tools, and service support at a time when the firm’s earnings per share,...

Fiserv (FISV) has had a rough stretch, with the stock down about 68% over the past year even as the underlying business keeps grinding out modest revenue and profit growth. Investors are wondering what they are missing. See our latest analysis for Fiserv. The latest leg lower leaves Fiserv trading at $65.73, and while the 7 day share price return of 4.85% hints at a tentative bounce, the 1 year total shareholder return of negative 67.60% and 5 year total shareholder return of negative 42.15%...

Key Insights Institutions' substantial holdings in Gilat Satellite Networks implies that they have significant...

In November 2025, Sarepta Therapeutics announced that the FDA had approved dosing in Cohort 8 of its ENDEAVOR trial, allowing evaluation of an enhanced immunosuppression regimen for ELEVIDYS in non-ambulant Duchenne muscular dystrophy patients, after the therapy had already been used in over 1,100 individuals worldwide. This regulatory step could be important for understanding how to extend ELEVIDYS beyond ambulant patients while managing safety issues such as liver injury, thrombocytopenia,...

Despite an already strong run, G. Willi-Food International Ltd. ( NASDAQ:WILC ) shares have been powering on, with a...

Werner Enterprises (WERN) has been grinding through a tricky freight backdrop, yet the stock has quietly climbed about 12% over the past month and 6% in the past 3 months. See our latest analysis for Werner Enterprises. That recent 7 day share price return of 7.8% and 1 month share price return of 11.8% look more like a relief rally than a full trend change, given the share price is still down year to date and the 1 year total shareholder return sits firmly negative. If Werner’s move has you...

In recent months, Clear Secure has continued to beat consensus revenue and EPS estimates while analysts now expect double-digit revenue and earnings growth, and CLEAR also announced a partnership with TidalHealth to use its identity verification technology to simplify patient access. These developments highlight how CLEAR is extending its secure identity platform beyond airports into healthcare while sustaining consistent forecast-beating financial performance, underscoring the breadth of...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

The Morning Bull - US Market Morning Update Tuesday, Dec, 9 2025 US stock futures are edging higher this morning, with S&P 500 contracts up about 0.1 percent, as investors weigh booming global tech demand against rising borrowing costs. Taiwan just reported record November exports of 64 billion US dollars, up 56 percent from a year ago, a sign of powerful demand for chips and electronics that supports US technology and semiconductor names. At the same time, the US 10 year Treasury yield has...

In recent months, Alignment Healthcare has reported strong operational progress, growing its Medicare Advantage customer base to about 229,600 members and moving from losses to profitability, supported by a much stronger free cash flow margin. This shift marks a meaningful turning point for the business, suggesting its technology-enabled care model is starting to convert rapid membership growth into sustainable earnings and cash generation. Building on this profitability inflection and...

Key Insights Ralliant's estimated fair value is US$54.87 based on 2 Stage Free Cash Flow to Equity With US$51.33 share...

We wouldn't blame Caterpillar Inc. ( NYSE:CAT ) shareholders if they were a little worried about the fact that Andrew...

As the European market navigates mixed returns with hopes of interest rate cuts from major economies, investors are keenly observing opportunities that may arise from undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be a strategic move, as these equities might offer potential for growth when market conditions stabilize.